PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials
Crossref DOI link: https://doi.org/10.1007/s40264-015-0296-6
Published Online: 2015-05-20
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Swiger, Kristopher J.
Martin, Seth S.
Text and Data Mining valid from 2015-05-20